InsiderSignal.AI

InsiderSignal.ai

AKTS - Aktis Oncology, Inc.

Insider Purchase by Gadicke Ansbert (10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Gadicke Ansbert, serving as 10% owner at Aktis Oncology, Inc. (AKTS), purchased 1,112,777 shares at $18.00 per share, for a total transaction value of $20,029,986.00. Following this transaction, Gadicke Ansbert now holds 10,260,064 shares of AKTS.

This purchase represents a 12.00% increase in Gadicke Ansbert's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, January 12, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 14, 2026, 2 days after the trade was made.

Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gadicke Ansbert

10%

Ansbert Gadicke, M.D. is a prominent biotech venture capitalist, founder of MPM Capital in 1992, and current Managing Partner of MPM BioImpact (formerly BioImpact Capital).[[1]](https://www.ornatx.com/members/ansbert-gadicke/)[[2]](https://milkeninstitute.org/speakers/ansbert-gadicke)[[3]](https://mpmbioimpact.com/team/ansbert-gadicke-m-d/) He has been the lead investor and board member for successful biopharma companies including BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix (acquired by Merck), Pharmasset (acquired by Gilead, developer of Hepatitis C cure Sovaldi), Mitobridge (acquired by Astellas), Cullinan Oncology (NASDAQ: CGEM), ElevateBio, and Orna Therapeutics, where he serves as Chairman and Co-Founder.[[1]](https://www.ornatx.com/members/ansbert-gadicke/)[[3]](https://mpmbioimpact.com/team/ansbert-gadicke-m-d/) Gadicke holds an M.D. from J.W. Goethe University in Frankfurt and conducted research at the Whitehead Institute (MIT), Harvard Biochemistry, and the German Cancer Research Center under Nobel Laureate Harald zur Hausen on HPV16/18, with publications in *Nature* and *Cell*.[[1]](https://www.ornatx.com/members/ansbert-gadicke/)[[2]](https://milkeninstitute.org/speakers/ansbert-gadicke) Prior to MPM, he worked at The Boston Consulting Group. He serves on the Harvard Medical School Board of Fellows and Massachusetts General Hospital Research Advisory Council, and received the 2017 Global Oncology Visionary Award. As a 10% Owner and Director, he has engaged in insider trading at companies like Cullinan Oncology and is linked to recent activity at Aktis Oncology, Inc. (AKTS).[[4]](https://www.quiverquant.com/insiders/1134655/ANSBERT-GADICKE)[[5]](https://www.gurufocus.com/insider/26985/ansbert-gadicke)

View full insider profile →

Trade Price

$18.00

Quantity

1,112,777

Total Value

$20,029,986.00

Shares Owned

10,260,064

Trade Date

Monday, January 12, 2026

85 days ago

SEC Filing Date

Wednesday, January 14, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Aktis Oncology, Inc.

Company Overview

No company information available
View news mentioning AKTS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3106600

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime